Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IST:GENIL)

Turkey · Delayed Price · Currency is TRY

10.94

+0.07 (0.64%)

At close: Aug 14, 2026

-15.28% (1Y)

Market Cap	49.19B -15.4%
Revenue (ttm)	23.27B +17.5%
Net Income	1.18B +61.2%
EPS	n/a
Shares Out	4.50B
PE Ratio	41.73
Forward PE	n/a
Dividend	0.05 (0.44%)
Ex-Dividend Date	Aug 4, 2026

Volume	52,566,105
Open	10.91
Previous Close	10.87
Day's Range	10.54 - 11.05
52-Week Range	7.12 - 14.93
Beta	-0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About IST:GENIL

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, tra... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1997

Employees 678

Stock Exchange Istanbul Stock Exchange

Ticker Symbol GENIL

Full Company Profile

Financial Performance

In 2025, IST:GENIL's revenue was 19.18 billion, a decrease of -0.59% compared to the previous year's 19.29 billion. Earnings were 814.44 million, an increase of 318.50%.

Financial Statements